Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Daniel A. Etra
AddedMar 31, 2024
UpdatedMay 31, 2026
Daniel A. Etra

Daniel A. Etra

Board Member, Epi One

CrunchbaseLinkedIn

Daniel A. Etra's Career

Epi One
Epi One

New York City, NY, US

Board Member· Board
RethinkFirst
RethinkFirst

New York City, NY, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Daniel A. Etra's Career

Epi One
Epi One
Series B$22.9M362016New York City, NY, US
Board Member· Board

Leadership at Epi One

Nina TandonNina TandonCo-Founder
Sarindr BhumiratanaSarindr BhumiratanaCo-Founder
Bob LangerBob LangerBoard Member
Elma HawkinsElma HawkinsBoard Member
Sophia F. F.Sophia F. F.Board Member
Michael MarquardtMichael MarquardtBoard Member

Similar to Epi One

EpinomaEpinomaSan Francisco, CA, USCancer Diagnosticsest. 2020EpinomaSan Francisco, CA, US · est. 2020

Innovative diagnostics company using multi-omics for cancer monitoring. Founded in 2020, based in San Francisco.

Pre-Seed · $125k6
Epic SciencesEpic SciencesSan Diego, CA, USCancer Diagnosticsest. 2008Epic SciencesSan Diego, CA, US · est. 2008

Epic Sciences: A medical diagnostics firm specializing in circulating tumor cell analysis.

Series G · $219.5M114
EmpiriEmpiriHouston, TX, USCancer Treatmentest. 2018EmpiriHouston, TX, US · est. 2018

Empiri: A biotech firm innovating personalized cancer treatments through predictive drug response tools.

Seed · $250k9
Episteme PrognosticsEpisteme PrognosticsNew York City, NY, USBiomarkers, Cancer Testsest. 2019Episteme PrognosticsNew York City, NY, US · est. 2019

Episteme Prognostics: Precision medicine firm developing therapeutic biomarkers for pancreatic cancer.

Series A · $4.1M6
RethinkFirst
RethinkFirst
Private Equity$12.4M1722007New York City, NY, US
CEO· C-Suite · Management

Leadership at RethinkFirst

Matt GreenfieldMatt GreenfieldFounder

Similar to RethinkFirst

Autism F.I.R.S.T.Autism F.I.R.S.T.Chantilly, VA, USTherapy, Treatmentest. 2021Autism F.I.R.S.T.Chantilly, VA, US · est. 2021

Autism F.I.R.S.T.: Providing collaborative autism therapy, treatment, advocacy, and support.

Seed · $350k14
Soar HealthSoar HealthDenver, CO, USAutism Therapy, Diagnosticsest. 2020Soar HealthDenver, CO, US · est. 2020

Soar Autism Center: Providing therapy and diagnostic services for children with autism.

Series A · $18.2M177
iTherapyiTherapyVallejo, CA, USTechnology, Therapyest. 2016iTherapyVallejo, CA, US · est. 2016

iTherapy provides multi-sensory tech for students with autism and special needs.

Pre-Seed · $1.4M9
Owl InsightsOwl InsightsSeattle, WA, USBehavioral Health, Softwareest. 2011Owl InsightsSeattle, WA, US · est. 2011

Owl Insights: A SaaS platform for measurement-based care in behavioral health treatment.

Series B · $16.4M23

Daniel A. Etra's Similar Executives & Operators

Willix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Daniel A. Etra

Matt JozwiakMatt JozwiakCEO · Rethink FoodChristopher O'DonovanChristopher O'DonovanCo-Founder · Rethink WaterKen CopeKen CopeFounder · REth!nkTina ManiTina ManiCEO · YFretGreg CarlisleGreg CarlisleCEO · RazorthinkScott CaseScott CaseCo-Founder & CEO · Recurrent